FOXOOTCServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as FOXOW
FOXO TECHNOLOGIES INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.10−0.01 (-9.09%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
FOXO TECHNOLOGIES INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Health Cares [Member] | $16.09M | $4.02M | – | – | 98.3% | +300.3% |
| Life Science Services [Member] | $252.50K | – | – | – | 1.5% | – |
| Corporate Segment and Other Operating Segment [Member] | $15.09K | – | – | – | 0.1% | – |
| Labs [Member] | $13.92K | $32.64K | – | – | 0.1% | -57.3% |
| Other Operating Segment [Member] | – | – | $145.00K | $511.00K | – | – |
| Labs and Life [Member] | – | $32.64K | $145.29K | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Epigenetic biomarker services [Member] | – | – | $99.00K | $400.00K | – | – |
| Epigenetic biomarker royalties [Member] | – | – | $27.00K | $83.00K | – | – |
| Life insurance commissions [Member] | – | – | $19.00K | $28.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Foxo Technologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.